Two-step acquisition of resistance to the teicoplanin-gentamicin combination by VanB-type Enterococcus faecalis in vitro and in experimental endocarditis.
The activity of vancomycin and teicoplanin combined with gentamicin was investigated in vitro against strains of Enterococcus faecalis resistant to vancomycin and susceptible to teicoplanin (VanB type) and against mutants that had acquired resistance to teicoplanin by three different mechanisms. In vitro, gentamicin selected mutants with two- to sixfold increases in the level of resistance to this antibiotic at frequencies of 10(-6) to 10(-7). Teicoplanin selected teicoplanin-resistant mutants at similar frequencies. Both mutations were required to abolish the activity of the gentamicin-teicoplanin combination. As expected, simultaneous acquisition of the two types of mutations was not observed. In therapy with gentamicin or teicoplanin alone, each selected mutants in three of seven rabbits with aortic endocarditis due to VanB-type E. faecalis BM4275. The vancomycin-gentamicin combination selected mutants that were resistant to gentamicin and to the combination. In contrast, the teicoplanin-gentamicin regimen prevented the emergence of mutants resistant to one or both components of the combination. These results suggest that two mutations are also required to suppress the in vivo activity of the teicoplanin-gentamicin combination.
Institut National de la Santé et de la Recherche Médicale, Hôpital Bichat-Claude Bernard, Paris, France.
A
A
Lefort
M
M
Baptista
B
B
Fantin
F
F
Depardieu
M
M
Arthur
C
C
Carbon
P
P
Courvalin
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001426:Bacterial Proteins / Q000096:biosynthesis* / Q000235:genetics; D015169:Colony Count, Microbial; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination / Q000494:pharmacology* / Q000627:therapeutic use; D004697:Endocarditis, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D013293:Enterococcus faecalis / Q000187:drug effects* / Q000235:genetics; D005839:Gentamicins / Q000494:pharmacology* / Q000627:therapeutic use; D008826:Microbial Sensitivity Tests; D009154:Mutation; D011817:Rabbits; D046929:Serine-Type D-Ala-D-Ala Carboxypeptidase; D017334:Teicoplanin / Q000494:pharmacology* / Q000627:therapeutic use; D013997:Time Factors
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D005839:Gentamicins; D017334:Teicoplanin; D046929:Serine-Type D-Ala-D-Ala Carboxypeptidase; C091956:VanX dipeptidase